Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Avantor, Inc. (NYSE:AVTR) announced the election of Emmanuel Ligner to its board of directors, with his initial term set to begin on August 18, 2025, and expire at the company’s 2026 annual meeting of stockholders. The appointment was made by the board of directors following a recommendation from its nominating and governance committee.
According to a statement included in a press release and recent SEC filing, Mr. Ligner will also serve as Avantor’s president and chief executive officer, as previously disclosed in a Form 8-K filed on July 21, 2025. His appointment as director fills a vacant seat on the board.
The company reported that Mr. Ligner will not receive additional compensation for his service as a director. Details regarding his employment terms as president and chief executive officer are outlined in the earlier CEO appointment filing and will be further detailed in the company’s quarterly report on Form 10-Q for the quarter ending September 30, 2025.
Avantor stated that there are no arrangements or understandings with other parties related to Mr. Ligner’s selection as a director, and he does not have a material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
The information in this article is based on a press release statement and the company’s Form 8-K filing with the Securities and Exchange Commission.
In other recent news, Avantor has announced that Emmanuel Ligner will take over as CEO on August 18, following a statement addressing activist investor Engine Capital. The company outlined its strategic initiatives, including a $400 million cost transformation program and a significant debt reduction of nearly $1.5 billion over the past 18 months. Engine Capital, which holds a 3% stake in Avantor, is advocating for strategic changes or a potential sale to enhance shareholder value, suggesting the share price could reach between $22 and $26 by 2027. Meanwhile, RBC Capital has lowered its price target for Avantor to $17 from $20, citing revenue headwinds and a miss in second-quarter earnings for 2025. Stifel also reduced its price target to $12, expressing concerns over bioprocess growth and a lowered organic growth and margin outlook. Additionally, UBS adjusted its price target to $13, highlighting risks related to market headwinds and potential sales growth challenges. Despite these adjustments, RBC Capital maintains an Outperform rating, while Stifel and UBS hold a Hold and Neutral rating, respectively. These developments reflect the ongoing challenges and strategic considerations facing Avantor.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.